文献速递类风湿关节炎

类风湿关节炎中骨密度与自身抗体的关联

Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2021-05-10

研究在荷兰408例和瑞典198例早期类风湿关节炎(RA)队列中,采用双能X线吸收法(DXA)随访5年和10年,评估抗环瓜氨酸蛋白抗体(ACPA)等自身抗体与骨密度的纵向关联。结果显示ACPA阳性者基线骨密度显著较低,但未伴随更快的骨密度下降。

要点

  • ACPA阳性RA患者基线左髋骨密度和Z评分显著低于ACPA阴性者。
  • ACPA阳性与随访期间骨密度或Z评分的下降速度无关。
  • 在疾病活动得到良好控制的治疗患者中,ACPA单独似乎不导致发病后骨丢失。

核心结论

  • ACPA的存在与RA患者基线骨密度显著较低相关,但与随访期间更大的骨密度下降无关。
  • 在疾病活动得到良好管理的治疗RA患者中,ACPA单独似乎不促进发病后的骨丢失。

研究设计与样本

  • 研究纳入荷兰408例早期RA患者随访5年和瑞典198例早期RA患者随访10年,采用腰椎和左髋双能X线吸收法(DXA)测量骨密度。
  • 使用广义估计方程评估ACPA及其他自身抗体对多项骨密度指标的纵向影响。

主要发现

  • 荷兰队列中,ACPA阳性者基线左髋估计边际平均骨密度为0.92 g/cm2(95%CI 0.91-0.93),低于ACPA阴性者的0.95 g/cm2(95%CI 0.93-0.97)(P=0.01)。
  • 荷兰队列中,ACPA阳性者基线左髋估计边际平均Z评分为0.18(95%CI 0.08-0.29),低于ACPA阴性者的0.48(95%CI 0.33-0.63)(P<0.01)。
  • ACPA阳性与随访期间绝对骨密度或Z评分的更大下降无关,且骨密度与更高水平的ACPA或其他自身抗体(类风湿因子和抗氨甲酰化蛋白抗体)无关。
  • 瑞典队列中,ACPA阳性者基线骨量减少患病率趋于更高(P=0.04),但ACPA阳性与随访期间骨量减少或骨质疏松患病率增加无关。

临床怎么用

  • 对ACPA阳性早期RA患者应关注基线骨密度评估,但无需因ACPA阳性而预期更快的骨密度下降。
  • 在疾病活动良好控制的情况下,ACPA阳性本身不构成发病后骨丢失的独立驱动因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Autoantibodies, such as anti-citrullinated protein antibodies (ACPAs), have been described as inducing bone loss in rheumatoid arthritis (RA), which can also be reflected by bone mineral density (BMD). We therefore examined the association between osteoporosis and autoantibodies in two independent RA cohorts. METHODS: Dual x-ray absorptiometry (DXA) of the lumbar spine and left hip was performed in 408 Dutch patients with early RA during 5 years of follow-up and in 198 Swedish patients with early RA during 10 years of follow-up. The longitudinal effect of ACPAs and other autoantibodies on several BMD measures was assessed using generalized estimating equations. RESULTS: In the Dutch cohort, significantly lower BMD at baseline was observed in ACPA-positive patients compared to ACPA-negative patients, with an estimated marginal mean BMD in the left hip of 0.92 g/cm2 (95% confidence interval [95% CI] 0.91-0.93) versus 0.95 g/cm2 (95% CI 0.93-0.97) (P = 0.01). In line with this, significantly lower Z scores at baseline were noted in the ACPA-positive group compared to the ACPA-negative group (estimated marginal mean Z score in the left hip of 0.18 [95% CI 0.08-0.29] versus 0.48 [95% CI 0.33-0.63]) (P < 0.01). However, despite clear differences at baseline, ACPA positivity was not associated with greater decrease in absolute BMD or Z scores over time. Furthermore, there was no association between BMD and higher levels of ACPAs or other autoantibodies (rheumatoid factor and anti-carbamylated protein antibodies). In the Swedish cohort, ACPA-positive patients tended to have a higher prevalence of osteopenia at baseline (P = 0.04), but again, ACPA positivity was not associated with an increased prevalence of osteopenia or osteoporosis over time. CONCLUSION: The presence of ACPAs is associated with significantly lower BMD at baseline, but not with greater BMD loss over time in treated RA patients. These results suggest that ACPAs alone do not appear to contribute to bone loss after disease onset when disease activity is well-managed.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Amkreutz JAMP, de Moel EC, Theander L, et al. Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2021. PMID: 33314699. doi:10.1002/art.41623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。